IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
February 23, 2026
– Practice integrated neurology network expands enrollment capacity –
New resource available view now
New resource available view now
– Practice integrated neurology network expands enrollment capacity –
POTOMAC, MARYLAND – February 17, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that the Canadian Intellectual Property Office (“CIPO”) has issued a Notice of Allowance covering the proprietary composition underlying IGC-AD1, the Company’s Phase 2 clinical stage program for agitation associated with Alzheimer’s disease. With this allowance, patent No. 3,095,729, titled “Method and Composition
POTOMAC, MARYLAND – February 12, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Wednesday, February 18, 2026, at 1:00 p.m. ET. IGC Pharma’s management will
POTOMAC, Maryland – February 09, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced the expansion of its Phase 2 CALMA trial for IGC-AD1 into Colombia, South America, through the addition of Grupo de Neurociencias de Antioquia (“GNA”). This expansion marks a pivotal operational milestone as IGC enters a region internationally recognized for its unique, genetically linked Alzheimer’s population. The GNA site is the latest addition to a
POTOMAC, MARYLAND – February 2, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today reported it has reached approximately 70% of planned patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer’s disease.
POTOMAC, MARYLAND – January 22, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (“AI”) to develop innovative treatments for Alzheimer’s disease, today announced the addition of Integrative Clinical Trials,
Hybrid Trial Model Enhances Participant Access, Retention, and Enrollment Efficiency Across Underserved and Rural Communities
POTOMAC, MARYLAND – January 6, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer’s disease,
New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer’s Drug Development
New Patent Expands IGC Pharma’s Pharmaceutical Cannabinoid Portfolio Beyond Alzheimer’s Disease